https://www.selleckchem.com/pr....oducts/hmpl-504-azd6
The authors describe here their GMP- and European Pharmacopoeia-compliant production and quality control process, report on a pre-clinical dose selection study and present the first in-human results. Together, these data substantiate the idea that ABCB5 MSCs manufactured as ATMPs could deliver a clinically relevant wound closure strategy for patients with chronic therapy-resistant wounds. The authors describe here their GMP- and European Pharmacopoeia-compliant production and quality control process, report on a pre-c
Like
Comment
Share
